Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

摘要: The efficacy of the newly developed pheochromocytoma-seeking radiopharmaceutical, [131I]MIBG, was examined in first 400 patients (441 studies) investigated for suspected pheochromocytoma at our institution. results [131I]MIBG scintigraphy were classified as true positive, false negative, and negative. Using this classification sensitivity found to be 78.4% primary, sporadic pheochromocytoma, 92.4% malignant 94.3% familial giving an overall 87.4%. specificity 98.9% 100% pheochromocytoma. 98.9%. Iodine-131 MIBG thus a safe, noninvasive, efficacious technique location pheochromocytomas, especially those arising from nonadrenal sites, recurring postoperatively, exhibiting metastatic disease. We find that, where available, is study choice initiate